METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)

Patent metadata

Field	Value
Publication number	US-2022389505-A1
Application number	US-202217812915-A
Country	US
Kind code	A1
Filing date	Jul 15, 2022
Priority date	Feb 1, 2013
Publication date	Dec 8, 2022
Grant date	—

Abstract

High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.

First claim

1 . A method for producing human retinal pigment epithelial (RPE) cells, comprising:
(a) culturing human induced pluripotent stem cells (hiPSCs) in a human embryonic stem cell culture medium comprising human basic fibroblast growth factor (bFGF) and not containing ingredients obtained from non-human animals to produce small embryoid bodies of 200-500 cells; (b) culturing the small embryoid bodies from step (a) in a first medium comprising retinal induction medium (RIM) and rock inhibitor (RI), wherein the RIM comprises a Wnt inhibitor, a Nodal pathway inhibitor, and 1 to 3% v/v knockout serum replacement, wherein the Nodal pathway inhibitor is SB-431542 or SB-505124, to form embryoid bodies that have increased efficiency of RPE differentiation; (c) culturing the embryoid bodies that have increased efficiency of RPE differentiation from step (b) on a matrigel coated tissue culture substrate-in a second medium comprising a retinal differentiation medium that does not comprise basic fibroblast growth factor (bFGF) and comprises Dickkopf-related protein 1 (DKK1), the Wnt inhibitor, a bFGF inhibitor, and Noggin, wherein the bFGF inhibitor is PD0325901 or PD98059, to form differentiating RPE cells that express PAX6 and MITF; (d) culturing the differentiating RPE cells from step (c) in a third medium comprising retinal media comprising Activin A and Wnt3a to produce cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency; and (e) culturing the cells that have increased expression of MITF and PAX6 and increased RPE differentiation efficiency from step (d) in a fourth medium comprising a RPE cell medium comprising a non-canonical Wnt 5a inducer, a canonical Wnt inhibitor, SU5402, and cyclopamine to produce human RPE cells that express TYR, TYRP1, MYRIP, Cadherin 1 or Cadherin 1 and TRPMI 1 or TRPMI 3, thereby producing human RPE cells.

2 . The method of claim 1 , wherein the Wnt inhibitor is N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide (CK1-7), 3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one (XAV939), Secreted frizzled-related protein (SFRP) 1, SFRP-2, SFRP-3, SFRP-4 or SFRP-5

3 . The method of claim 1 , wherein the Nodal pathway inhibitor is SB-431542.

4 . The method of claim 3 , wherein the first medium comprises 3.5 to 9 mM of SB-431542.

5 . The method of claim 1 , wherein the retinal induction medium does not comprise serum.

6 . The method of claim 1 , wherein the inhibitor of bFGF is PD032590.

7 . The method of claim 6 , wherein the second medium comprises 0.5 to 2 mM of PD0325901.

8 . The method of claim 1 , wherein the first medium comprises 50 ng/ml of Dickkopf-related protein 1 (DKK1).

9 . The method of claim 1 , wherein the third medium comprises 100 to 200 ng/ml of Activin A.

10 . The method of claim 1 , wherein the third medium comprises 75 to 150 ng/ml of Wnt3a.

11 . The method of claim 1 , wherein the second medium comprises 75 to 150 ng/ml of DKK1.

12 . The method of claim 1 , wherein the fourth medium comprises 75 to 150 ng/ml of WNT5a, 75 to 150 ng/ml of DKK1, 5 μM Cycolopamine and 10 μM of SU5402.

13 . The method of claim 1 , wherein step (a) comprises culturing the cells in the presence of 1.5% v/v knock out serum replacement.

14 . The method of claim 1 , wherein the tissue culture substrate is a transwell plate.

15 . The method of claim 1 , further comprising expressing OCT4, SOX2, LIN28 and Nanog in a human fetal RPE cell to produce the human induced pluripotent stem cells.

16 . The method of claim 1 , wherein the human induced pluripotent stem cells comprise a nucleic acid encoding a marker operably linked to a RPE cell specific promoter.

17 . The method of claim 17 , wherein the retinal specific promoter is a tyrosinase promoter.

18 . The method of claim 1 , wherein the embryoid bodies are cultured in the first medium for 48 hours.

19 . The method of claim 1 , wherein the embryoid bodies are cultured in the second medium for 18 to 24 days.

20 . The method of claim 19 , wherein the embryoid bodies are cultured in the second medium for three weeks.

21 . The method of claim 1 , wherein the differentiating RPE cells are cultured in the third medium for 18 to 24 days.

22 . The method of claim 21 , wherein the differentiating RPE cells are cultured in the third medium for three weeks.

23 . The method of claim 1 , wherein the cells are cultured in the fourth medium for 12 to 16 days.

24 . The method of claim 23 , wherein the cells are cultured in the fourth medium for two weeks.

25 . The method of claim 1 , further comprising maintaining the RPE cells in the fourth medium and 5% v/v fetal serum.

26 . The method of claim 25 , comprising maintaining the RPE cells in fourth medium and 5% v/v fetal serum for six to eight weeks.

Assignees

• The Us Secretary Department Of Health And Human Servic

Inventors

• Bharti Kapil
• Davis Janine
• Maminishkis Arvydas
• Ferrer-Alegre Marc
• Miller Sheldon S

Classifications

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12N2501/16

  Activin; Inhibin; Mullerian inhibiting substance · CPC title

• C12N2506/45

  from artificially induced pluripotent stem cells · CPC title

• C12Q1/6881 Primary

  for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes · CPC title